Pediatric acute myeloid leukemia (AML) is a heterogeneous malignant disease, characterized by abnormal proliferation and impaired differentiation of myeloid cells. Acquired cytogenetic aberrations such as t(8;21)(q22;q22)/AML-ETO, inv(16)(p13q22)/ CBFb-MYH11, t(15;17)(q22;q21)/PML-RARa, rearrangements involving MLL and molecular aberrations in genes such as FLT3, NPM1, CEBPA and WT1 are involved in AML pathogenesis and are prognostic factors for treatment outcome.
The telomerase complex is expressed in highly proliferative cells, and is responsible for maintaining telomeres, which cap the ends of chromosomes and protect genomic DNA from eroding during cell divisions. Impaired telomerase function can result in extremely short telomeres, limiting the proliferative capacity of progenitor cells, and may lead to chromosomal instability, thus predisposing to malignant transformation. 2 This pathogenesis is manifested in dyskeratosis congenita, an inherited bone marrow (BM) failure syndrome in which patients are at increased risk for malignancies, including AML, and in which telomerase complex mutations are etiologic. 2 To date, the significance of telomerase complex mutations as risk factor for AML in children is unknown. Furthermore, although extremely short telomeres in leukemic cells of adult AML patients have been reported to be associated with cytogenetic aberrations and complex karyotype, the clinical implications of these short telomeres are unknown. 3, 4 In the current study, we assessed the frequency of mutations in the telomerase complex genes TERT, telomerase reverse transcriptase, and TERC, the RNA template of the telomerase complex, in pediatric AML. Furthermore, we measured telomere length in pediatric AML patients at diagnosis and determined its relationship with clinical and molecular characteristics and outcome.
The frequency of mutations in TERT and TERC was determined as previously described 1 in diagnostic BM or peripheral blood (PB) samples obtained from a representative cohort (Supplementary  Table S1 ) of 168 de novo pediatric AML cases, who were enrolled in consecutive DCOG, AML-BFM and LAME treatment protocols between 1987 and 2008. Samples contained, after enrichment, 80% or more leukemic cells. No mutations in TERC were detected. In TERT, three non-synonymous variants were present in a total of eight patients (carrier frequency 0.048). In one patient, a novel heterozygous variant in a well-conserved amino acid in exon 2 in the N-terminal extension of TERT, E327D (mRNA NM_198253.2: 1039G/T), was detected. Telomerase activity of this variant, as determined in reconstitution assays in telomerase-deficient VA13 cells, 1 was similar to wild-type TERT (94.7±3.5% (mean±s.d.)). Furthermore, a heterozygous variant in exon 6 in the reverse transcriptase domain of TERT, T726M (mRNA NM_198253.2: 2235C/T), was found in another patient. T726M, located in the reverse transcriptase domain of telomerase, was not associated with reduced telomerase activity. 5 Both mutations were absent among 406 Dutch adult blood donors. Remission material to confirm germline origin of these mutations was not available in the two patients. Six of 168 patients carried a heterozygous variant in the C-terminal extension of TERT, A1062T (mRNA NM_198253.2: 3242G/A; carrier frequency 0.036). A1062T was also the most common gene variant in adult AML (n ¼ 594; minor allele frequency (MAF) 0.019), with a frequency three times higher than in ethnicity and/or geographically matched controls (n ¼ 1110; MAF 0.006). 1 In contrast, A1062T was present in a similar carrier frequency in pediatric AML patients (0.048) as in 406 Dutch controls (0.049), composed of two independent cohorts (6/192 (0.031) and 14/214 (0.065)). In three of the six patients carrying A1062T, remission material (o1% blasts by flow cytometry immunophenotyping) was available, confirming germline origin of the variant. Telomerase activity of A1062T was reported normal 6 or decreased to 60% of wild type. 1 Clinical characteristics of patients carrying TERT variants are described in Supplementary Table S2 . Other variants, all reported in healthy controls and not associated with reduced telomerase function, 5 were present in this cohort and are described in Supplementary  Table S3 . MAFs of two synonymous variants and variant A279T in patients were similar in controls, demonstrating comparability of both cohorts (Supplementary Table S3 ).
Our data are in contrast to adult AML patients, in whom constitutional TERT mutations appear to be a risk factor for AML. 1 Although variants E327D and T726M were absent in healthy controls, the relationship of these variants to the etiology of AML is dubious, as the variants showed normal telomerase function when assayed in vitro, karyotype was normal in both patients and telomere lengths of leukemic cells were within the third quartile of the total cohort. Furthermore, the most common variant in our cohort, A1062T, was present in a comparable frequency in geographically matched controls, and thus, at least in our pediatric AML cohort, it cannot be regarded as a pathologic variant. The carrier frequency of A1062T (0.049) in Dutch blood bank donors is remarkably higher than the MAF of 0.006 in controls in the adult AML study, 1 but comparable to a carrier frequency of 0.036 in 600 German controls 7 and 0.031 in 477 white controls from the NCI PLCO Cancer Screening Trial. 8 This might suggest that in individuals of Caucasian descent, or within specific ethnic sub-populations, the A1062T variant may be less pathogenic than previously thought.
Although mutations in the telomerase complex genes TERT and TERC are infrequent events in pediatric AML, we investigated whether short telomeres in leukemic cells are associated with AML characteristics or contribute to an adverse outcome. Telomere length was successfully determined by quantitative PCR, as previously described, 8 with some modifications in leukemic cells derived from 167 pediatric AML patients at diagnosis. Median telomere length (T/S ratio) was 0.65 (range: 0.28-2.3). When compared with healthy control PB leukocytes, telomere length in leukemic cells was very short (Figure 1a) , confirming previous reports. 3, 4, 9 Because age at diagnosis was not associated with telomere length (Figure 1a ), patients were categorized into quartiles based on telomere length without age-adjustment (Table 1) . There was no difference in distribution of sex or white blood cell count among the quartiles. When evaluated as a continuous variable, there was no difference in telomere length among FAB types, nor among AML characteristic cytogenetic subgroups (Figures 1b and c) . Telomere lengths between prognostic relevant molecular subgroups, determined as described, Telomere length was not associated with the number of cytogenetic aberrations (numerical and/or structural), including complex karyotype, defined as three or more cytogenetic aberrations (Figure 1e ). These findings are in contrast to adult AML, where patients with an aberrant karyotype had significantly shorter leukemic cell telomeres than did normal karyotype patients, 3, 4 suggesting that short telomeres in AML might induce chromosomal instability. A limitation of our approach is that we studied average leukemic cell telomere length; however, the shortest telomere per cell seems to determine the chromosomal stability. 11 Future studies might benefit from single telomere length analysis, in which telomere lengths and fusion events at specific chromosomes can be determined. 12 To gain insight into mechanisms that might contribute to the differences in telomere length in AML blast cells, expression levels, determined by microarray analysis (in 157/167 patients; HGU133 Plus 2.0 microarray, Affymetrix), 13 of telomere biology-related genes were correlated with telomere length. Expression levels of TERF1, TERF2, TINF2 and POT1 (components of the shelterin complex); WDR79 or TCAB1 (facilitating trafficking of telomerase to Cajal bodies); and TERT, DKC1, NHP2, NOP10 and GAR1 (components of the telomerase complex) did not correlate with telomere length (Supplementary Table S4 ).
To assess the influence of telomere length on clinical outcome, telomere length quartiles 2-4 were grouped and compared with telomere length quartile 1. Five-year pOS in quartile 1 versus quartiles 2-4 (50 ± 8 versus 61 ± 5%), pEFS (40 ± 8 versus 44 ± 5%), and cumulative incidence of relapse and non-response (50 ± 8% versus 44±5%) were not significantly different (Supplementary Figure S1) . That short telomeres of leukemic cells do not correlate with unfavorable outcome is in accordance with a smaller study in adult AML, 4 but in contrast to studies in B-CLL and CML. 14, 15 To summarize, in pediatric AML, variants in the telomerase complex genes TERT and TERC do not seem to be a risk factor for developing AML. Clinically, loss-of-function mutations in TERC or TERT might increase the risk of chemotherapy-related toxicity and are relevant in selecting sibling donors for hematopoietic stem cell transplantation. However, given the results of this study, in the absence of classical features of dyskeratosis congenita, or a family history positive for BM failure, liver cirrhosis or pulmonary fibrosis, screening for mutations in TERT or TERC in sporadic AML cases does not seem relevant. Short telomeres correlate with the high-risk molecular aberration FLT3/ITD, but survival is not significantly influenced by telomere length in this pediatric AML cohort. We conducted a clinical trial utilizing the platform of proteosome inhibition with bortezomib þ histone deacetylase inhibition with vorinostat in relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) based on the potential target of nuclear factor-kappaB. 1,2 The study rationale was based on published single-agent efficacy of the agents in AML and high-risk MDS, [3] [4] [5] [6] [7] [8] and safety data for the combination in other malignancies. [9] [10] [11] [12] [13] [14] [15] Between August 2009 and May 2012, a total of 16 patients, aged 18 or older, were enrolled on this study at the University of Minnesota. The trial was registered with NCI clinicaltrials.gov no. NCT00818649.
Patients were treated with vorinostat 400 mg daily on days 1-14 and bortezomib 1.3 mg/m 2 IV on days 1,4,8 and 11 of a 21-day cycle. Pretherapy bone marrow assessments and transfusion requirements were documented. Disease response assessments were done after three cycles or at trial exit if fewer than three cycles were completed. Clinical responses were defined as complete morphologic remission (CR), partial remission (PR) and hematologic improvement (HI). Stable disease (SD) and progressive disease (PD) were also noted. Completion of at least one full cycle was required to be evaluable for analysis of clinical response. All patients were included in toxicity assessment.
Bryant and Day's two-stage Phase II was used for this study to monitor both response rate and toxicity. On the basis of this twostage optimal design, a maximum of 46 patients with high-risk MDS and relapsed/refractory AML were needed. Of them, 21 patients were to be accrued during stage I, and 25 patients during stage II. Excess toxicity was defined as any toxicity that required permanently stopping the study drug, required three or more dose reductions, or where patient death occurred that was possibly attributable to the study therapy and not due to PD. Specific stopping rules were in place for the study. For stage 1, the study would be terminated for failed efficacy if only one patient had a clinical response or for toxicity if eight or greater had excess toxicity. SAS 9.2 (Cary, NC, USA) was used for the statistical analyses.
A total of 16 patients began therapy, but only 12 completed at least one cycle of therapy to be eligible for response evaluation. The patients were at a median age of 65.5, were 50% female and predominantly white (94%). Karnofsky performance status was a median of 85 (range 70-100). Medically significant comorbidities Accepted article preview online 28 February 2013; advance online publication, 26 March 2013
